Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begins

Genmab A/S stock (ISIN DK0010272202) is trading near USD 34.15 for its Nasdaq-listed American Depositary Shares around mid-September 2026, a level that sits below prevailing analyst price targets and frames a fresh Phase 3 trial start for its antibody petosemtamab as a key catalyst for investors as of September 15, 2026.

Analysts lift earnings estimates and maintain upside targets

According to Ad-hoc-news on September 16, 2026, HC Wainwright has raised its Q3 2026 earnings per share (EPS) estimate for Genmab from USD 0.37 to USD 0.49, an increase of USD 0.12 that corresponds to roughly 32.4 percent growth against the previous forecast for the quarter.

The same note cited by Ad-hoc-news reports that HC Wainwright has simultaneously reaffirmed its Buy rating on Genmab stock and kept its USD 40.00 price target unchanged for the Nasdaq-listed American Depositary Shares as of mid-September 2026, positioning the shares with implied upside relative to the latest trading levels.

Measured against the USD 34.15 opening level for Genmab ADRs on Nasdaq on the most recent trading day highlighted in the analyst overview, the maintained USD 40.00 price target from HC Wainwright points to potential appreciation of USD 5.85 per share, or about 17.1 percent, if the stock were to reach that target at some point in the future.

As Ad-hoc-news further summarizes based on MarketBeat data, Genmab A/S currently carries a consensus rating of Moderate Buy among covering analysts, with a consensus price target of USD 39.50 for its Nasdaq-listed ADRs, only slightly below HC Wainwright's USD 40.00 level.

The same consensus overview shows that, relative to the USD 39.50 average target, the USD 34.15 opening price on the most recent trading day implies a discount of USD 5.35, corresponding to around 15.7 percent potential upside to the broader analyst community's view, underscoring that Genmab stock trades below where many analysts value the shares as of mid-September 2026.

Petosemtamab Phase 3 colorectal cancer trial starts

Alongside the supportive analyst stance, Genmab has a fresh clinical development catalyst from its pipeline. According to BioSniper on September 17, 2026, Genmab's Phase 3 second-line colorectal cancer trial of petosemtamab plus chemotherapy versus comparator arms in RAS/BRAF wild-type disease started on September 15, 2026, marking a key advancement of the asset into late-stage testing.

The trial described by BioSniper is designed as a second-line study in colorectal cancer that will compare petosemtamab combined with chemotherapy against regimens including cetuximab or bevacizumab in patients whose tumors are RAS and BRAF wild-type, a genetically defined subgroup that may be particularly responsive to antibody-based approaches.

For investors, the move of petosemtamab into Phase 3 in colorectal cancer creates a new value inflection point, since late-stage trials can underpin potential future regulatory filings and commercial opportunities if they demonstrate meaningful benefit over existing standards of care, while simultaneously adding execution risk around trial timelines and eventual readouts.

This petosemtamab program sits alongside Genmab's established antibody portfolio and newer collaborations, and the explicit registration of the Phase 3 trial start on September 15, 2026 gives a concrete date that investors can use as a reference for tracking subsequent development milestones, such as enrollment progress, interim analyses or eventual top-line data.

Valuation context and recent share price levels

Genmab's Nasdaq-listed ADRs (ticker GMAB) provide the main reference price for international investors. Per Nasdaq data compiled by Yahoo Finance, the shares closed at USD 34.40 on Nasdaq on September 16, 2026, up USD 0.25 or 0.73 percent compared with the previous close of USD 34.15.

The same quote overview on Yahoo Finance shows a 52-week high of USD 39.14 and, by implication from the 52-week range around the current level, a 52-week low below the latest trading price; at USD 34.40 as of September 16, 2026, Genmab stock therefore trades about USD 4.74, or roughly 12.1 percent, below its recent 52-week high.

In the same data snapshot, Yahoo Finance reports an average analyst price target of USD 39.14 for Genmab ADRs, which aligns closely with the USD 39.50 consensus level cited by MarketBeat and summarized by Ad-hoc-news, and further reinforces that the USD 34.40 closing price leaves room for potential upside in the eyes of many analysts.

Although the exact market capitalization figure is not detailed in the snippets, the combination of a mid-USD 30s share price and Genmab's share count means the company continues to represent a multi-billion USD biotechnology franchise, with valuation anchored by commercialized antibody products, royalties from partnered programs and the pipeline assets such as petosemtamab now moving into Phase 3.

Fundamental backdrop and earnings expectations

The HC Wainwright upward revision to Q3 2026 EPS expectations, from USD 0.37 to USD 0.49, suggests that the analyst now anticipates stronger profitability in the near-term quarter than previously assumed, whether through higher revenue, improved margins or a more favorable mix of royalty and collaboration income, although the detailed drivers are not fully elaborated in the summary.

Relative to typical patterns for Genmab's quarterly results, an EPS of USD 0.49 in Q3 2026 would represent a meaningful improvement on many historical quarters and, if realized, could contribute to full-year earnings growth and potentially support a higher valuation multiple, particularly when coupled with continued pipeline progress.

At the same time, the fact that HC Wainwright maintained rather than increased its USD 40.00 price target indicates a balance between improved near-term earnings assumptions and broader risk considerations, including competition in oncology and immunology, regulatory uncertainties and the execution risks associated with multiple late-stage trials such as the newly started petosemtamab Phase 3 program.

The Moderate Buy consensus rating reported by MarketBeat and summarized by Ad-hoc-news signals that, while several analysts see Genmab stock as attractive at current levels, there are also more neutral views in the coverage universe, reflecting both the company's opportunities in antibody-based therapies and the typical volatility of biotech earnings and trial outcomes.

Risk factors around clinical development and valuation

For investors, one important counter-factor to the bullish earnings and target narrative is the inherent risk in late-stage drug development. The petosemtamab Phase 3 colorectal cancer trial, despite being a notable advancement and catalyst announced on September 15, 2026, will require substantial time, capital and operational focus, and positive data are not guaranteed.

In addition, Genmab's valuation already embeds expectations for continued growth in existing marketed products and royalties, so any disappointment in commercial trends or setbacks in other pipeline programs could weigh on the shares even if petosemtamab progresses smoothly through its newly started Phase 3 study.

Competitive dynamics in colorectal cancer, where other targeted therapies and immuno-oncology agents are active, also mean that petosemtamab must demonstrate a clear clinical and possibly biomarker-defined advantage to secure strong uptake if ultimately approved, a challenge that investors will monitor closely as the Phase 3 trial enrolls and eventually reports results.

Genmab stock level as of the latest Nasdaq close

At the latest completed Nasdaq session referenced in the available price data, Genmab ADRs closed at USD 34.40 on September 16, 2026, with that level serving as a practical reference point for investors comparing the stock to the USD 40.00 price target from HC Wainwright and the roughly USD 39.50 consensus target summarized by MarketBeat, as well as to the 52-week high of USD 39.14 shown in the Yahoo Finance overview.

More news and analyses on Genmab stock